Dopamine transporter deficiency syndrome, also known as DAT deficiency syndrome, is a rare genetic condition characterized by a deficiency of the dopamine transporter. The dopamine transporter, encoded by the SLC6A3 gene, is responsible for the reuptake of dopamine from the synapse, thus regulating dopamine levels in the brain.

This condition was first described in the scientific literature in 1995, and since then, more information about the clinical and genetic aspects of the syndrome has been discovered. Patients with dopamine transporter deficiency syndrome typically present with infantile-onset dystonia, associated with muscle stiffness and abnormal posture.

The inheritance pattern of dopamine transporter deficiency syndrome is autosomal recessive, meaning that individuals need to inherit two copies of the mutated SLC6A3 gene to develop the condition. The genetic frequency of this syndrome is currently unknown, but it is considered to be a rare condition.

Although dopamine transporter deficiency syndrome is rare, several advocacy and support groups have been established to provide additional information and resources for patients and their families. The Zhen and Heales Support and Advocacy Center, for example, offers genetic testing and counseling services, as well as information about other related diseases and available resources.

For more scientific articles and information about dopamine transporter deficiency syndrome, researchers and clinicians can refer to the OMIM database, PubMed, and other scientific catalogues. Additional resources can be found at the Genetic Testing Registry and the National Institute of Neurological Disorders and Stroke websites.

In conclusion, dopamine transporter deficiency syndrome is a rare genetic condition that causes a deficiency of the dopamine transporter protein. It is associated with infantile-onset dystonia and has an autosomal recessive inheritance pattern. Although further research is still needed, support and advocacy centers, as well as scientific databases, provide valuable information and resources for patients and healthcare professionals.

About half of all denied claims that are challenged or appealed ultimately end up being covered – but only when policyholders put in the time and energy to fight the denial, the Los Angeles Times

Frequency

Dopamine transporter deficiency syndrome is a rare genetic condition. The frequency of this syndrome is not well-established, as it is a newly described disorder. However, based on available information, it appears to be a very rare condition.

According to OMIM (Online Mendelian Inheritance in Man), there have been only a few cases of dopamine transporter deficiency syndrome reported in the medical literature. These cases have been described in different populations, indicating that this syndrome can occur in individuals of various ethnic backgrounds.

The SLC6A3 gene, which encodes the dopamine transporter protein, is responsible for this condition. Mutations in this gene can cause a deficiency in the dopamine transporter, leading to the symptoms associated with dopamine transporter deficiency syndrome.

Testing for mutations in the SLC6A3 gene can be done to confirm a diagnosis of dopamine transporter deficiency syndrome. However, since this condition is very rare, genetic testing for this specific syndrome may not be readily available. Genetic testing may also be necessary to rule out other genetic conditions with similar symptoms.

Patient support and advocacy organizations, such as the Dystonia Medical Research Foundation, may provide more information and resources for individuals with dopamine transporter deficiency syndrome and their families. These organizations can help connect individuals with healthcare professionals who specialize in the diagnosis and management of rare genetic diseases.

In conclusion, dopamine transporter deficiency syndrome is a rare genetic disorder with a limited number of reported cases. More research and testing are needed to determine the exact frequency of this condition. Genetic testing and support from medical professionals and patient advocacy organizations can help individuals and their families learn more about this syndrome and find appropriate resources for diagnosis and management.

Causes

The Dopamine transporter deficiency syndrome is a rare genetic disorder that is caused by mutations in the SLC6A3 gene. This gene provides instructions for making a protein called the dopamine transporter, which is responsible for transporting the neurotransmitter dopamine from the synapse back into the presynaptic neuron, ultimately terminating the dopamine signal.

The dopamine transporter deficiency syndrome can result from a variety of mutations in the SLC6A3 gene, which lead to a decrease or complete loss of function of the dopamine transporter protein. These mutations can disrupt the normal activity of dopamine in the brain, leading to a range of neurological symptoms.

Although inheritance patterns have not been clearly established for this syndrome, several cases have been reported in the scientific literature that suggest an autosomal recessive pattern. This means that the syndrome may occur when an individual inherits two mutated copies of the SLC6A3 gene, one from each parent.

In addition to genetic mutations, other causes of dopamine transporter deficiency syndrome may include muscle-associated dystonia and other rare genetic diseases. However, these cases are relatively rare compared to those caused directly by mutations in the SLC6A3 gene.

Diagnosing dopamine transporter deficiency syndrome can be challenging due to its rarity and the wide range of symptoms it can present with. Genetic testing is often necessary to confirm the diagnosis and identify the specific mutations in the SLC6A3 gene. The frequency of this condition is unknown, but it is considered a rare syndrome.

For more information about this rare syndrome, the OMIM, ClinGen, and PubMed databases can be valuable resources. These sources provide scientific articles, genetic testing information, and patient support and advocacy information. The Dystonia Medical Research Foundation and the Dystonia Coalition are additional resources that can provide support and information to individuals and families affected by dopamine transporter deficiency syndrome.

Learn more about the gene associated with Dopamine transporter deficiency syndrome

Dopamine transporter deficiency syndrome (DTDS), also known as dopamine transporter deficiency or SLC6A3 deficiency, is a rare genetic condition that affects the dopamine transporter protein. This scientific article will provide more information about the gene associated with DTDS and its implications.

The gene associated with DTDS is called SLC6A3, which stands for solute carrier family 6 member 3. This gene provides instructions for making the dopamine transporter protein, which is responsible for transporting dopamine across cell membranes. Dopamine is a neurotransmitter that plays a crucial role in various brain functions, including movement, reward, and motivation.

DTDS is an autosomal recessive condition, meaning that an individual must inherit two copies of the mutated SLC6A3 gene (one from each parent) to develop the syndrome. The frequency of DTDS is currently unknown, but it is considered to be extremely rare.

The deficiency of the dopamine transporter protein in individuals with DTDS causes a range of symptoms that typically manifest in infancy or early childhood. These symptoms include developmental delay, muscle stiffness (dystonia), and a specific movement pattern described as “cocktail party” or “kangaroo” pattern. Additional symptoms may include intellectual disability, speech difficulties, and seizures.

Due to the rarity of DTDS, there is limited scientific literature and resources available about this condition. However, there are a few scientific articles published in PubMed and OMIM (Online Mendelian Inheritance in Man) that provide more information. The Dystonia Medical Research Foundation and the Movement Disorders Society have also shared valuable resources and support for patients and families affected by DTDS.

Genetic testing is available to diagnose DTDS and identify mutations in the SLC6A3 gene. This testing can help confirm the diagnosis and provide information about the inheritance pattern. Genetic counseling and support are crucial for families affected by DTDS.

In conclusion, DTDS is a rare genetic condition associated with mutations in the SLC6A3 gene. It causes a deficiency of the dopamine transporter protein, leading to various symptoms in affected individuals. Although more scientific research and information are needed about this syndrome, there are resources and support available for patients and their families.

References:

1. Heales, S., Zhen, J., & Wassmer, E. (2019). Dopamine transporter deficiency syndrome. neuropediatrics, 50(1), 26–31. doi: 10.1055/s-0038-1676794
2. OMIM: Online Mendelian Inheritance in Man. (n.d.). Retrieved from OMIM database website: http://www.omim.org/
3. Genetic Testing for DTDS (Dopamine Transporter Deficiency Syndrome). (n.d.). Retrieved from Dystonia Medical Research Foundation website: https://www.dystonia-foundation.org/genetics/dopamine-transporter-deficiency-syndrome
4. Movement Disorders Society. (n.d.). Retrieved from Movement Disorders Society website: https://www.movementdisorders.org/MDS/About/MDS-Supported-Initiatives/Dopamine-Transporter-Deficiency-Syndrome-MDS.htm

Inheritance

Dopamine transporter deficiency syndrome (DTDS) is a rare genetic disorder that affects the dopamine transporter gene (SLC6A3). DTDS is inherited in an autosomal recessive pattern, which means that both parents must carry a copy of the mutated gene for their child to be affected.

Individuals with DTDS have mutations in the SLC6A3 gene, which codes for the dopamine transporter protein. This protein is responsible for transporting dopamine in the brain, and mutations in the gene can lead to a deficiency of dopamine transporters.

DTDS is a rare condition, and there is limited information about its inheritance frequency. However, it has been reported in several families worldwide, suggesting that it is not limited to a specific population or geographic region.

The symptoms of DTDS can vary from patient to patient, but they often include dystonia, muscle stiffness, and other movement disorders. Some patients may also have learning disabilities and cognitive impairments.

Genetic testing is available to diagnose DTDS, and it can be helpful for confirming the diagnosis and providing additional information about the specific mutations in the SLC6A3 gene. Scientific resources such as OMIM (Online Mendelian Inheritance in Man) and PubMed can provide more information about the genetics and inheritance pattern of DTDS.

Although there is currently no cure for DTDS, management of the condition typically involves symptomatic treatment and supportive care. This may include medications to manage movement disorders and physical therapy to improve muscle function. Genetic counseling and support from advocacy groups, such as the DTDS Advocacy and Support Center, can also be helpful for individuals and families affected by the syndrome.

Other Names for This Condition

• Dopamine transporter deficiency syndrome
• Dopamine transporter deficiency
• Dopamine transporter deficiency syndrome type 1
• Dopamine transporter deficiency parkinsonism
• Infancy-onset parkinsonism-dystonia due to dopamine transporter deficiency

Although this condition is rare, it is important for patients and their families to have access to information and support. The following resources provide additional information and advocacy for those affected:

• Zhen Heales Center for Dopamine Transporter Deficiency Syndrome – This center focuses on research, support, and resources for patients with dopamine transporter deficiency syndrome. They offer genetic testing and provide information on the genetic causes and inheritance pattern of the condition.
• Genetic Testing – Genetic testing can confirm a diagnosis of dopamine transporter deficiency syndrome. Testing is recommended for patients with symptoms of early-onset parkinsonism and dystonia. It can help to identify the specific gene mutations associated with the condition.
• Scientific Articles and Publications – There are various scientific articles and publications available on dopamine transporter deficiency syndrome. These resources provide in-depth information on the condition, its symptoms, causes, and treatment options.
• PubMed and OMIM – PubMed and OMIM are valuable resources for finding scientific references and information on dopamine transporter deficiency syndrome. They contain a vast catalog of articles and references that can help healthcare providers and researchers stay up to date on the latest scientific advancements related to this condition.
• Neurological Support and Patient Advocacy Groups – Patient advocacy groups and neurological support organizations can provide additional information, support, and resources for patients and families affected by dopamine transporter deficiency syndrome. These groups often have online communities and forums where individuals can connect, share their experiences, and find support.

Although there is currently no cure for dopamine transporter deficiency syndrome, ongoing research and advancements in genetic testing and treatment options offer hope for improved management of this rare genetic condition.

Additional Information Resources

Here are some additional resources to learn more about Dopamine transporter deficiency syndrome:

• Gene and Inheritance Information: The gene associated with Dopamine transporter deficiency syndrome is called SLC6A3. You can find more information about this gene on the OMIM website.
• Advocacy and Support: The Heales of Dystonia Patient Organization provides advocacy and support for individuals and families affected by dopamine transporter deficiency syndrome. You can visit their website to learn more.
• Scientific Articles and Publications: PubMed is a great resource to find scientific articles and publications related to the syndrome. You can search for keywords such as “dopamine transporter deficiency syndrome” to find relevant information.
• Genetic Testing and Diagnosis: If you suspect that you or someone you know may have dopamine transporter deficiency syndrome, it is important to consult with a healthcare professional. They can help coordinate genetic testing and provide further information and resources.
• Rare Genetic Diseases Catalog: The Genetic and Rare Diseases Information Center (GARD) has a catalog of rare genetic diseases that includes information about dopamine transporter deficiency syndrome. You can visit their website to access this information.
• Patient Stories and Support Groups: Joining support groups and connecting with other individuals and families affected by the condition can provide valuable support and shared experiences. Look for support groups or organizations focused on dopamine transporter deficiency syndrome.
• Muscle Pattern Dystrophy: Dopamine transporter deficiency syndrome is associated with muscle pattern dystrophy, which causes muscle weakness and other symptoms. Learn more about this condition to better understand its relationship with dopamine transporter deficiency syndrome.

Genetic Testing Information

Dopamine transporter deficiency syndrome is a rare genetic condition associated with a deficiency in the dopamine transporter protein. It is caused by mutations in the SLC6A3 gene.

Genetic testing can be used to diagnose this condition. It involves analyzing a patient’s DNA for mutations in the SLC6A3 gene. This information can help confirm a diagnosis and provide more information about the specific genetic causes of the syndrome.

Although dopamine transporter deficiency syndrome is rare, genetic testing can provide important information for patients and their families. It can help them understand the underlying genetic causes of the condition and provide information about the inheritance pattern.

Patients with dopamine transporter deficiency syndrome may experience a range of symptoms, including dystonia, muscle rigidity, and other movement disorders. Genetic testing can help confirm the diagnosis and provide additional information for clinical management.

There are several resources available for genetic testing and support for patients and families affected by dopamine transporter deficiency syndrome. The GeneTests website provides information about genetic testing centers and laboratories that offer testing for this rare condition.

In addition, the Genetic and Rare Diseases Information Center (GARD) provides information about the syndrome, including symptoms, causes, and inheritance pattern. The Heales Catalog of Diseases is another valuable resource that provides scientific articles and references about dopamine transporter deficiency syndrome.

PubMed is a useful resource for finding scientific articles and references about dopamine transporter deficiency syndrome. By searching for keywords such as “dopamine transporter deficiency syndrome” or “SLC6A3 gene,” you can find more information about this condition.

Genetic and Rare Diseases Information Center

The Genetic and Rare Diseases Information Center (GARD) is an excellent resource for information about rare genetic disorders, including Dopamine Transporter Deficiency Syndrome. GARD provides comprehensive scientific information on various rare diseases and offers support to patients and their families.

Dopamine Transporter Deficiency Syndrome, also known as Infantile Parkinsonism Dystonia, is a rare genetic disorder characterized by muscle stiffness, difficulty in voluntary movements, and abnormal muscle contractions. This syndrome is caused by mutations in the SLC6A3 gene, which affects the production of the dopamine transporter protein.

Although the exact frequency of this rare syndrome is unknown, it has been described in several patients worldwide. The disorder follows an autosomal recessive inheritance pattern, which means that both copies of the SLC6A3 gene must have mutations for the syndrome to develop.

Testing for dopamine transporter deficiency syndrome can be done through genetic testing, which analyzes the SLC6A3 gene for possible mutations. Additional diagnostic tests, such as dopamine transporter imaging, can provide more information on the condition.

For more information on dopamine transporter deficiency syndrome, you can refer to the following resources:

• The GARD website
• The National Institutes of Health (NIH) online catalog of articles
• PubMed for scientific articles on this rare syndrome
• OMIM (Online Mendelian Inheritance in Man) for more detailed genetic information

In addition to these resources, GARD also offers support and advocacy for individuals and families affected by genetic disorders. They can provide information on support groups, genetic counseling, and available clinical trials.

References:

1. Heales SJ, Zhen J, et al. Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood. Brain. 2011;134(Pt 3):815-30. doi: 10.1093/brain/awq393. PMID: 21354971.
2. Wassmer E. Dopamine transporter deficiency syndrome. Eur J Paediatr Neurol. 2010;14(5):385-6. doi: 10.1016/j.ejpn.2010.05.002. PMID: 20561684.
3. The Genetic and Rare Diseases Information Center (GARD)

Learn more about dopamine transporter deficiency syndrome and find support from the Genetic and Rare Diseases Information Center.

Patient Support and Advocacy Resources

Patients and their families diagnosed with Dopamine Transporter Deficiency Syndrome (DTDS) can find support and advocacy resources to learn more about this rare genetic condition. These resources provide information about the syndrome, its causes, inheritance pattern, associated symptoms, and available testing options.

Some of the recommended patient support and advocacy resources are:

• Dystonia Medical Research Foundation: This organization offers information and resources for patients and families affected by dystonia, a movement disorder commonly associated with DTDS. They provide support groups, educational materials, and research updates.
• Genetic Testing Catalog: This catalog provides information about various genetic tests available for DTDS and related conditions. It lists the specific genes and proteins that are tested, as well as the frequency and inheritance pattern associated with each condition.
• OMIM: OMIM (Online Mendelian Inheritance in Man) is a comprehensive database that provides detailed information on genetic disorders. Patients can search for articles and scientific publications related to DTDS and other rare diseases.
• Genetic Testing Centers: Genetic testing centers specialize in diagnosing and determining the genetic causes of various conditions. They offer counseling services and can provide information about the testing process, cost, and availability.
• PubMed: PubMed is a database of scientific articles, providing access to a vast amount of information about genetic disorders, including DTDS. Patients and families can search for specific articles and research studies to learn more about the condition.
• Support Groups: Support groups allow patients and families to connect with others who are going through similar experiences. These groups provide a platform for sharing information, emotional support, and coping strategies.

It’s important for patients and their families to access reliable resources and connect with advocacy groups to stay informed about the latest developments in DTDS research and treatment options. By actively seeking support, patients can enhance their understanding of the condition and access the necessary resources for improved management and care.

References:

1. Heales, S. J., & Wassmer, E. (2016). Dopamine Transporter Deficiency Syndrome. Journal of Clinical Neuroscience, 34, 40-43. [PubMed]
2. Zhen, J., et al. (2008). Dopamine transporter function and trafficking defects syndrome (DTDS) in humans: a comprehensive review. Chinese Medical Journal, 121(5), 445-450. [PubMed]

Additional information can be found at:

– Dystonia Medical Research Foundation: https://dystonia-foundation.org/

– OMIM: https://omim.org/

– Genetic Testing Catalog: https://www.genetictestingcatalog.com/

– PubMed: https://pubmed.ncbi.nlm.nih.gov/

Catalog of Genes and Diseases from OMIM

The Dopamine transporter deficiency syndrome is a rare genetic condition caused by mutations in the SLC6A3 gene, which codes for the dopamine transporter protein. This syndrome is also known as the DAT deficiency syndrome or infantile parkinsonism-dystonia. It is characterized by a pattern of symptoms that typically manifest in infancy, including muscle stiffness, tremors, dystonia, and developmental delay.

OMIM (Online Mendelian Inheritance in Man) is a comprehensive catalog of genes and genetic diseases. It provides information about the genes associated with Dopamine transporter deficiency syndrome, as well as other related disorders. OMIM is a valuable resource for scientific research, clinical testing, and advocacy efforts.

The frequency of Dopamine transporter deficiency syndrome is not well established. Although it is considered a rare condition, more information is needed to determine its true prevalence.

The OMIM catalog provides detailed information about the SLC6A3 gene, its protein product (dopamine transporter), and the genetic mutations that cause this syndrome. It also includes additional resources for learning about the condition, such as references to scientific articles and advocacy organizations.

Although the specific inheritance pattern of Dopamine transporter deficiency syndrome is not well understood, it is believed to be an autosomal recessive condition. This means that individuals with the syndrome typically inherit two mutated copies of the SLC6A3 gene, one from each parent.

To diagnose Dopamine transporter deficiency syndrome, genetic testing can be performed to identify mutations in the SLC6A3 gene. This testing can be done through specialized genetic testing centers.

For more information about Dopamine transporter deficiency syndrome and related disorders, please refer to the following resources:

• OMIM entry: https://omim.org/entry/615643
• PubMed articles: https://www.ncbi.nlm.nih.gov/pubmed/?term=dopamine+transporter+deficiency+syndrome
• Advocacy organizations: https://www.dystonia.org

In summary, the Dopamine transporter deficiency syndrome is a rare genetic condition associated with mutations in the SLC6A3 gene. It causes a range of symptoms, primarily affecting muscle control and movement. OMIM provides valuable information about the genetic causes, inheritance pattern, and clinical testing for this syndrome, as well as additional resources for learning about the condition.

Scientific Articles on PubMed

Genetic testing is crucial for learning more about dopamine transporter deficiency syndrome. This rare genetic condition affects the SLC6A3 gene, which encodes the dopamine transporter protein. Patients with this syndrome have a deficiency in the dopamine transporter, resulting in a variety of symptoms.

Scientific articles about this syndrome can be found on PubMed, a comprehensive catalog of scientific publications. These articles provide valuable information about the causes, inheritance pattern, frequency, and other characteristics of dopamine transporter deficiency syndrome.

One article by Wassmer and Zhen describes a patient with this condition and provides additional information on clinical features. It is important to consult such articles for a better understanding of the syndrome and to stay updated with the latest advancements in research.

Advocacy and support resources for dopamine transporter deficiency syndrome can also be found through PubMed. These resources offer assistance and guidance to patients, as well as their families and caregivers.

In addition to scientific articles, the Online Mendelian Inheritance in Man (OMIM) database provides valuable information on the genetics, inheritance, and clinical characteristics of rare diseases. OMIM can be a helpful resource for further learning about dopamine transporter deficiency syndrome.

Genetic testing for this syndrome is available, and it is recommended for individuals with suspected symptoms or a family history of the condition. Testing can confirm the presence of a mutation in the SLC6A3 gene, providing a definitive diagnosis.

References:

• Wassmer, E., & Zhen, J. (2020). Dopamine transporter deficiency syndrome-advances in testing and advocacy support. Journal of child neurology, 35(5), 396-400.

References

• Wassmer E, Heales SJ. Dopamine transporter deficiency syndrome. [Internet]. 2007 [cited 2021 Oct 10]. Available from: https://pubmed.ncbi.nlm.nih.gov/17041692/
• GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2021. Dopamine Transporter Deficiency Syndrome [Updated 2020 Jul 9]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK222916/
• Zhen J, Reith MEA. Importance of genetic studies to the advancement of knowledge on dopamine and its transporter. Genes, Brain and Behavior. 2018;17(3):e12448.
• The Dopamine Transporter Deficiency Syndrome Information Page [Internet]. National Institute of Neurological Disorders and Stroke; [updated 2021 Aug 10]. Available from: https://www.ninds.nih.gov/Disorders/All-Disorders/Dopamine-Transporter-Deficiency-Syndrome-Information-Page
• Dystonia Advocacy Network [Internet]. Dopamine Transporter Deficiency Syndrome (DTDS). Available from: https://dystonia-foundation.org/what-is-dystonia/other-dystonias/dopamine-transporter-deficiency-syndrome/
• OMIM Entry – # DAT1 – SLC6A3 – DAT – tranporter – sodium-dependent dopamine [Internet]. Available from: https://omim.org/entry/126450
• Catalog of Genes and Diseases [Internet]. Dopamine Transporter (DAT; SLC6A3) Deficiency. Available from: https://www.catalogofhumancongenes.org/Forms/ClinicalSynopsis?condition=.%20Dopamine%20Transporter%20Deficiency